Wheeler Bio
Series A in 2025
Founded in 2020 by Jesse McCool in Oklahoma City, Wheeler Bio is a biomanufacturing company dedicated to expediting the translation of therapeutic innovations into clinical impact. It offers comprehensive discovery-to-IND programs and rapid, portable CMC platforms, bridging critical gaps between discovery and early development.
Wheeler Bio
Series A in 2022
Founded in 2020 by Jesse McCool in Oklahoma City, Wheeler Bio is a biomanufacturing company dedicated to expediting the translation of therapeutic innovations into clinical impact. It offers comprehensive discovery-to-IND programs and rapid, portable CMC platforms, bridging critical gaps between discovery and early development.
Vernal Biosciences
Venture Round in 2022
Vernal Biosciences specializes in producing high-purity messenger RNA (mRNA) for research and clinical applications. Its platform streamlines manufacturing processes, reducing uncertainty and development time in advanced therapeutics. Vernal offers flexible, high-quality mRNA supplies and services, allowing clients to conduct drug discovery and development without investing in dedicated teams or facilities.
Tegmine Therapeutics
Corporate Round in 2022
Tegmine Therapeutics is a private, seed-stage biotechnology company focused on developing antibody-based therapeutics that target proteins and their disease-related glycan modifications. The company employs a unique platform that integrates biology, mass spectrometry, and machine learning to identify tumor-specific protein modifications responsible for disease progression and severity. This innovative approach aims to facilitate the creation of next-generation antibody drugs that are specifically designed to target tumors while minimizing damage to healthy tissues. Through its research and development efforts, Tegmine Therapeutics seeks to contribute to more sustainable cancer and tumor therapies, enhancing treatment efficacy and patient outcomes.
Mytide Therapeutics
Series A in 2022
Mytide specializes in peptide synthesis and purification, aiming to facilitate diverse applications. They collaborate with partners to tackle challenges in peptide production, identify useful modifications, and design peptide libraries. Mytide offers a cloud platform for immediate ordering, properties calculation, order tracking, and interactive data display.
Wheeler Bio
Seed Round in 2022
Founded in 2020 by Jesse McCool in Oklahoma City, Wheeler Bio is a biomanufacturing company dedicated to expediting the translation of therapeutic innovations into clinical impact. It offers comprehensive discovery-to-IND programs and rapid, portable CMC platforms, bridging critical gaps between discovery and early development.
deepCDR Biologics
Acquisition in 2021
deepCDR Biologics AG is a biotechnology company established in 2018 and headquartered in Basel, Switzerland. The company specializes in antibody optimization and discovery services, utilizing advanced technologies to deliver scalable solutions for its clients. By focusing on innovative approaches in biologics, deepCDR Biologics aims to enhance the development process of therapeutic antibodies, catering to the growing demands of the biopharmaceutical industry.
Wheeler Bio
Funding Round in 2021
Founded in 2020 by Jesse McCool in Oklahoma City, Wheeler Bio is a biomanufacturing company dedicated to expediting the translation of therapeutic innovations into clinical impact. It offers comprehensive discovery-to-IND programs and rapid, portable CMC platforms, bridging critical gaps between discovery and early development.
Vernal Biosciences
Seed Round in 2021
Vernal Biosciences specializes in producing high-purity messenger RNA (mRNA) for research and clinical applications. Its platform streamlines manufacturing processes, reducing uncertainty and development time in advanced therapeutics. Vernal offers flexible, high-quality mRNA supplies and services, allowing clients to conduct drug discovery and development without investing in dedicated teams or facilities.